We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DiaSorin Enters Indian IVD Market

By LabMedica International staff writers
Posted on 01 Aug 2012
Print article
DiaSorin (Saluggia, Italy) continues its expansion plan in Asia through the establishment of a Joint Venture Company (JV) with local partner Trivitron Healthcare (Chennai, India), an Indian medical technology company focused on manufacturing and distribution, with solutions in the in vitro diagnostics business.

DiaSorin has signed a joint venture (JV) with Trivitron Healthcare to enter India's EUR 400 million IVD market. Financial terms were not available.

In accordance with the JV Agreement, DiaSorin Group and Trivitron Group formed the limited liability company dubbed DiaSorin Trivitron Healthcare Private Ltd., headquarted in Chennai, in which the companies have 51% and 49% share respectively. It will directly operate in the Indian diagnostics market.

Device and diagnostics companies have known for some time that they can make better progress in India, which is the world's second fastest growing IVD market after China, by joining forces with a local partner.

Carlo Rosa, CEO of DiaSorin Group, commented, "The JV agreement with Trivitron is really important for the success of DiaSorin Group in a such relevant market as India, and represents an important pillar of the current and future expansion strategy of DiaSorin Group in Asia Pacific. [….] By combining the quality of DiaSorin systems and tests to Trivitron’s extensive knowledge of the Indian market, I’m confident that India will represent another important leg of revenues for us in the Asian region."

DiaSorin is active internationally in the market for in vitro diagnostics and immunodiagnostics. It develops, on an ongoing basis, a vast and innovative line of products that are used in analysis laboratories at universities, hospitals, and private testing facilities.

Trivitron is a global medical technology company of Indian origin focused on manufacturing, innovation, and distribution. The key focus segments include cardiology & implantable devices, imaging sciences (IVD), diagnostics, critical life support solutions (CLSS), and ophthalmology and dental technologies.

Related Links:

DiaSorin
Trivitron Healthcare


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Centrifuge
Centrifuge 5430/ 5430 R
New
PSA Test
Human Semen Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.